GWGary P. Wormser

Gary P. Wormser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gary P. Wormser has a total of 173 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lyme disease: the great controversy.

    by J. J. Halperin, P. Baker, G. P. Wormser

    This chapter traces the origin of the clinical condition termed 'chronic Lyme disease' (CLD) and explores the various medical, political, and legal issues it has brought. It also provides a detailed examination of some of the key myths that together reinforced the recognition of CLD as a diagnosis. These myths include: seronegative Lyme disease; Lyme disease is a clinical diagnosis based entirely on symptomatology; the symptom described as 'brain fog'; the assertion that Lyme disease is a potentially lethal infection; prolonged or extended antibiotic therapy is better; and continuing non-specific symptoms being caused by bacterial persistence in the body.


  • Open Access

    Long-term Assessment of Health-Related Quality of Life in Patients With Culture-Confirmed Early Lyme Disease

    by Gary P. Wormser, Erica Weitzner, Donna McKenna, Robert B. Nadelman, Carol Scavarda, Irida Molla, Rhea Dornbush, Paul Visintainer, John Nowakowski

    The health-related quality of life of 100 subjects with culture-confirmed early Lyme disease enrolled in a prospective study with annual follow-up visits was evaluated using the 36-Item Short Form General Health Survey version 2 (SF-36v2) questionnaire at 11–20 years after diagnosis. The mean summary scores of physical and mental health were similar to those of the general population.


  • Long-term Assessment of Fatigue in Patients with Culture-confirmed Lyme Disease

    by Gary P. Wormser, Erica Weitzner, Donna McKenna, Robert B. Nadelman, Carol Scavarda, John Nowakowski


  • Open Access

    Brief Report: Long‐Term Assessment of Fibromyalgia in Patients With Culture‐Confirmed Lyme Disease

    by Gary P. Wormser, Erica Weitzner, Donna McKenna, Robert B. Nadelman, Carol Scavarda, Shimon Farber, Priya Prakash, Julia Ash, John Nowakowski

    Objective: Fibromyalgia (FM) occurs in 2–8% of the general population, and one of the triggers may be Lyme disease. The aim of this study was to evaluate for FM in patients with culture‐confirmed Lyme disease.Methods: Patients with culture‐confirmed Lyme disease who originally presented with erythema migrans were enrolled in a prospective study between 1991 and 2000 and have been evaluated annually to determine their long‐term outcomes. In 2011–2013, the patients were evaluated for FM, by both interview and tender point examination.Results: Among the 100 patients assessed, 52% were male, and the mean age was 64.9 years (median 64 years [range 42–86 years]). The mean duration of followup was 15.4 years (median 16 years [range 11–20 years]). At least 24 of the patients (24%) had experienced a second episode of erythema migrans before being evaluated for fibromyalgia. One patient (1% [95% confidence interval 0.025–5.4%]) met the criteria for fibromyalgia. In this patient, the symptoms consistent with fibromyalgia began >19 years after Lyme disease was diagnosed.Conclusion: Fibromyalgia was observed in only 1% of 100 patients with culture‐confirmed early Lyme disease; this frequency is consistent with that observed in the general population.


  • Utility of serodiagnostics designed for use in the United States for detection of Lyme borreliosis acquired in Europe and vice versa

    by Gary P. Wormser, Aimee T. Tang, Natasha R. Schimmoeller, Susan Bittker, Denise Cooper, Paul Visintainer, Maria E. Aguero-Rosenfeld, Katarina Ogrinc, Franc Strle, Gerold Stanek

    Although two-tier testing is standard practice in both the United States and Europe for the serologic diagnosis of Lyme borreliosis (LB), the test kits generally differ. The purpose of this study was to determine if the testing used in the United States will detect LB acquired in Europe and vice versa. Testing was performed on a convenience sample of archived sera from 40 LB patients from Austria and 39 from the United States, using first- and second-tier test kits from both the United States and Europe. The sensitivity of four first-tier tests from Europe and two first-tier tests from the United States was similar. Thus, two-tier testing was compared to the C6 ELISA as the first-tier test, since it is licensed in both the United States and Europe. The sensitivity of C6 two-tier testing with US assays was 9/40 (22.5 % [95 % CI 10.8–38.5 %]) for detection of LB acquired in Europe, and just 20.0 % (95 % CI 2.5–55.6 %) in the ten European patients with neurologic involvement. These results differed significantly from the sensitivity of European C6 two-tier testing that was 70.0 % (95 % CI 53.5–83.4 %) overall (p < 0.001) and 90.0 % (95 % CI 55.5–99.7 %) for the European patients with neurologic manifestations specifically (p = 0.016). In contrast, the sensitivity of European and US C6 two-tier testing was similar for detection of LB acquired in the United States. Two-tier serologic testing with the US test kits may be unsatisfactory for detection of LB acquired in Europe. First-tier testing with an assay such as the C6 ELISA should be considered as a stand-alone diagnostic strategy in such cases.


  • Open Access

    Gender Disparity between Cutaneous and Non-Cutaneous Manifestations of Lyme Borreliosis

    by Franc Strle, Gary P. Wormser, Paul Mead, Kanthi Dhaduvai, Michael V. Longo, Omosalewa Adenikinju, Sandeep Soman, Yodit Tefera, Vera Maraspin, Stanka Lotrič-Furlan, et al.

    Cutaneous manifestations of Lyme borreliosis in Europe include erythema migrans (EM) and acrodermatitis chronica atrophicans (ACA); the most common non-cutaneous manifestations are Lyme neuroborreliosis (LNB) and Lyme arthritis. The purpose of this study was to evaluate the gender distribution of patients with these clinical manifestations of Lyme borreliosis. Data on gender were obtained from the clinical records of patients with Lyme borreliosis aged ≥15 years who had been evaluated at the University Medical Center Ljubljana, Ljubljana, Slovenia. Among 10,539 patients diagnosed with EM, 6,245 (59.3%) were female and among 506 ACA patients 347 (68.6%) were female. In contrast, among the 60 patients with Lyme arthritis only 15 (25%) were female (p<0.0001 for the comparison of gender with EM or ACA) and among the 130 patients with LNB only 51 (39.2%) were females (p<0.0001for the comparison of gender with EM or ACA). Although the proportion that was female in the LNB group was greater than that of patients with Lyme arthritis, this difference did not reach statistical significance (p = 0.10). Although older individuals are more likely to be female in the general Slovenian population, the age of patients with cutaneous versus non-cutaneous manifestations was not the explanation for the observed differences in gender. In conclusion, patients with cutaneous manifestations of Lyme borreliosis were predominantly female, whereas those with non-cutaneous manifestations were predominantly male. This provocative finding is unexplained but may have direct relevance to the pathogenesis of Lyme borreliosis.


  • Open Access

    Differences and Similarities between Culture-Confirmed Human Granulocytic Anaplasmosis and Early Lyme Disease

    by Gary P. Wormser, Maria E. Aguero-Rosenfeld, Mary E. Cox, John Nowakowski, Robert B. Nadelman, Diane Holmgren, Donna McKenna, Susan Bittker, Lois Zentmaier, Denise Cooper, et al.

    Lyme disease is transmitted by the bite of certain Ixodes ticks, which can also transmit Anaplasma phagocytophilum , the cause of human granulocytic anaplasmosis (HGA). Although culture can be used to identify patients infected with A. phagocytophilum and is the microbiologic gold standard, few studies have evaluated culture-confirmed patients with HGA. We conducted a prospective study in which blood culture was used to detect HGA infection in patients with a compatible clinical illness. Early Lyme disease was defined by the presence of erythema migrans. The epidemiologic, clinical, and laboratory features of 44 patients with culture-confirmed HGA were compared with those of a convenience sample of 62 patients with early Lyme disease. Coinfected patients were excluded. Patients with HGA had more symptoms ( P = 0.003) and had a higher body temperature on presentation ( P < 0.001) than patients with early Lyme disease. HGA patients were also more likely to have a headache, dizziness, myalgias, abdominal pain, anorexia, leukopenia, lymphopenia, thrombocytopenia, or elevated liver enzymes. A direct correlation between the number of symptoms and the duration of illness at time of presentation (rho = 0.389, P = 0.009) was observed for HGA patients but not for patients with Lyme disease. In conclusion, although there are overlapping features, culture-confirmed HGA is a more severe illness than early Lyme disease.


  • Why has Borrelia burgdorferi not been transmitted by blood transfusion?

    by Yelena Ginzburg, Debra Kessler, Steven Kang, Beth Shaz, Gary P. Wormser


  • Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease

    by Gary P. Wormser, Martin Schriefer, Maria E. Aguero-Rosenfeld, Andrew Levin, Allen C. Steere, Robert B. Nadelman, John Nowakowski, Adriana Marques, Barbara J.B. Johnson, J. Stephen Dumler